HEALTH PROFESSIONAL · SOURCE READING

Dacarbazine

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Chemotherapy

Dacarbazine was approved in 1970 based on overall response rates. Phase III trials indicated an overall response rate of 10% to 20%, with rare complete responses observed. An impact on OS has not been demonstrated in randomized trials.[33-36] When used as a control arm for registration trials of ipilimumab and vemurafenib in previously untreated patients with metastatic melanoma, dacarbazine was shown to be inferior for OS.

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice